Discussion
A pivotal Phase 3 clinical trial has begun dosing participants to evaluate MorphoSys‘s investigational antibody, MOR202 (TJ202), in combination with Revlimid (lenalidomide)…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Discussion
Discussion
OncLive, a digital resource platform for oncologists, will welcome 15 new members at its 7th Annual Giants of Cancer Care Winners Reception on May 30 in…
Discussion
ALLO-715, Allogene Therapeutics‘ donor-derived CAR T-cell therapy, can trigger a durable anti-tumor response in mice with multiple myeloma, and maintain its characteristics and…
Discussion
A triple regimen composed of Kyprolis (carfilzomib), thalidomide, and dexamethasone, given before and after high-dose chemotherapy and autologous stem cell transplant, is safe…
Discussion
Bluebird bio has officially opened a facility in Durham, North Carolina, to make the lentiviral vector needed for its investigational gene and cell treatments, including…
Discussion
Maintenance therapy with Ninlaro (ixazomib) can prolong and boost therapeutic responses from initial treatment in multiple myeloma patients who did not undergo an…
